Beam Therapeutics shows promise in gene therapy for sickle cell disease, but it also has high risks and market expectations.

NTLA stock falls more than 21% in a week after the company announced strategic priorities and key anticipated milestones for 2025. We advise prospective investors to stay on the sidelines for now.

France’s Sanofi – a major player in the rare disease category – is offering ... than current therapies for the disease, based on alpha-1 antitrypsin protein from the plasma of healthy ...

Moderna provides updates on its business and pipeline progress at the J.P. Morgan Healthcare Conference.

Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) has earned an average rating of “Moderate Buy” from the twelve ...

Although no cause of death or further details were given, the news comes months after Lynch announced he had been living with ...

Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company at the forefront of precision genetic medicines with a market capitalization of $1.87 billion, is navigating a critical juncture in its ...

Shares in Wave Life Sciences rose by 74% after it reported clinical data with a pioneering new RNA-editing therapy for alpha-1 antitrypsin ... out of a Huntington's disease alliance with the ...

Hennion & Walsh Asset Management Inc. lifted its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 125.2 ...

It was an extremely busy week in the biotech sector, with several companies making important presentations at the J.P. Morgan ...

LEGENDARY director David Lynch passed away at the age of 78, after revealing he’d suffered from a terrifying lung disease ...

A thorough nutrition assessment of a child with liver disease is essential. [11] This includes the collection of anthropometric and biochemical data, as well as a clinical, social, and dietary ...